Resilient Older Subjects with Heterozygous Familial Hypercholesterolemia, Baseline Differences and Associated Factors

Elisenda Climent,Antón González-Guerrero,Victoria Marco-Benedí,María-del-Mar García-Andreu,Juan Diego Mediavilla-García,Manuel Suárez-Tembra,David Benaiges,Xavier Pintó,Juan Pedro-Botet

DOI: https://doi.org/10.3390/ijms25094831

IF: 5.6

2024-04-30

International Journal of Molecular Sciences

Abstract:Despite elevated low-density lipoprotein (LDL) cholesterol levels, some older subjects with heterozygous familial hypercholesterolemia (HeFH) do not develop atherosclerotic cardiovascular disease (ACVD) during their lifetime. The factors related to this resilient state have not been fully established. The aim of this study was to evaluate differential characteristics between older HeFH subjects with and without ACVD and factors associated with the presence of ACVD. Subjects were part of the Spanish Atherosclerosis Society Dyslipidemia Registry, and those ≥ 70 years old and with HeFH were included. Baseline characteristics of these subjects with and without ACVD were compared. A multivariate analysis was performed to assess factors associated with the presence of ACVD. A total of 2148 subjects with HeFH were included. Resilient subjects were mostly female, younger and presented fewer comorbidities with respect to the ACVD group. Subjects without ACVD had higher baseline high-density lipoprotein (HDL) cholesterol (55.8 ± 17.1 vs. 47.9 ± 15.4 mg/dL; p < 0.001) and lower lipoprotein(a) [Lp(a)] (53.4 ± 67.9 vs. 66.6 ± 85.6 mg/dL; p < 0.001) levels with respect to those in the ACVD group. Lp(a) and the presence of ≥3 risk factors were associated with the presence of ACVD.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the baseline differences and related factors between individuals without atherosclerotic cardiovascular disease (ACVD) and those with ACVD in heterozygous familial hypercholesterolemia (HeFH) patients aged 70 and above. Specifically, the study aims to evaluate the differences in baseline characteristics between HeFH patients without and with ACVD among the elderly, and analyze the factors associated with the presence of ACVD. ### Research Background Heterozygous familial hypercholesterolemia (HeFH) is a common monogenic metabolic disorder, mainly manifested as an increase in low - density lipoprotein (LDL) cholesterol levels. This hypercholesterolemia significantly increases the risk of atherosclerotic cardiovascular disease (ACVD). Nevertheless, some elderly HeFH patients do not develop ACVD throughout their lives, a phenomenon known as the "resilient state". However, the factors contributing to this resilience have not been fully identified. ### Research Objectives 1. **Evaluate differences in baseline characteristics**: Compare the baseline characteristics of HeFH patients aged 70 and above without and with ACVD. 2. **Analyze related factors**: Through multivariate analysis, determine the factors associated with the presence of ACVD. ### Main Findings - **Differences in baseline characteristics**: - Patients without ACVD are mainly female, younger, and have fewer comorbidities. - The high - density lipoprotein (HDL) cholesterol level in the group without ACVD is higher (55.8 ± 17.1 vs. 47.9 ± 15.4 mg/dL; p < 0.001), while the lipoprotein(a) [Lp(a)] level is lower (53.4 ± 67.9 vs. 66.6 ± 85.6 mg/dL; p < 0.001). - **Related factors**: - Lp(a) level (OR 1.002, 95% CI: 1.000 - 1.004; p = 0.019) and the presence of ≥3 cardiovascular risk factors (OR 2.795, 95% CI: 1.950 - 4.005; p < 0.001) are significantly associated with the presence of ACVD. ### Conclusions The study found that among HeFH patients aged 70 and above, individuals without ACVD are mainly female, younger, have fewer comorbidities, and have higher HDL cholesterol levels and lower Lp(a) levels. These characteristics help to explain why some HeFH patients do not develop ACVD throughout their lives. In addition, Lp(a) level and the presence of multiple cardiovascular risk factors are independent predictors of the presence of ACVD. ### Clinical Significance Understanding these factors associated with the absence of ACVD can help identify high - risk patients who need more aggressive lipid - lowering treatment and provide a basis for the development of new preventive lipid - lowering therapies. Nevertheless, even in HeFH patients without ACVD, attention should still be paid to achieving the recommended LDL cholesterol target value to further reduce cardiovascular risk.

Resilient Older Subjects with Heterozygous Familial Hypercholesterolemia, Baseline Differences and Associated Factors

Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study

Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia

Familial Hypercholesterolemia in the Elderly: An Analysis of Clinical Profile and Atherosclerotic Cardiovascular Disease Burden from the Hellas-FH Registry

Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)

Early Atherosclerosis in Familial Hypercholesterolemia Patients: Significance of Vascular Markers for Risk Stratification

Association Between Patient Sex and Familial Hypercholesterolemia and Long-Term Cardiovascular Risk Factor Management 5 Years After Acute Coronary Syndrome

Role of HDL function and LDL atherogenicity on cardiovascular risk: A comprehensive examination

Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia

Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE

Dysfunctional High-Density Lipoproteins Are Associated With a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk: A Nested Case-Control Study

Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia

Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia

Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters

Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study

Communication: High-Density Lipoprotein-Specific Phospholipid Efflux in Familial Hypercholesterolemia

Gene expression profiling in elderly patients with familial hypercholesterolemia with and without coronary heart disease

INCREASED HDL CHOLESTEROL LEVELS RELATE TO ENDOTHELIAL GLYCOCALYX INTEGRITY IN OLDER TREATED PATIENTS WITH ESSENTIAL HYPERTENSION

Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia

Sex Differences in the Presentation, Treatment and Outcomes of Patients with Homozygous Familial Hypercholesterolemia

Persistence with long-term PCSK9 inhibitors treatment and its effectiveness in Familial Hypercholesterolemia: data from the SAFEHEART study.